A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

NCT05559580 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

214

Enrollment

INDUSTRY

Sponsor class

Conditions

Scleroderma, Systemic

Interventions

DRUG: Avenciguat (BI 685509)
DRUG: Placebo

Sponsor

Boehringer Ingelheim